Kennedy Jr. allows limited production of six wellness peptides

The Department of Health and Human Services announced on Tuesday that it will exercise enforcement discretion for six specific peptides. This policy effectively allows small compounding pharmacies to manufacture the substances, which have long been popular in wellness circles despite a previous official ban on their production.

The six peptides included in the policy are BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500. Proponents link these compounds to various health outcomes, including ulcerative colitis, insomnia, wound healing, metabolic health, and migraine relief. However, none of these substances have completed the Food and Drug Administration's rigorous drug review and approval process.

Health Secretary Robert F. Kennedy Jr. has been a vocal supporter of peptide use, noting that he has used some of the compounds himself. The administration argues that allowing compounding pharmacies to produce these items is a safer alternative to the illicit "research-use-only" products currently sold online. Those unregulated items are often sourced from overseas suppliers with variable quality standards.

The policy applies specifically to 503A compounding pharmacies, which are smaller facilities that prepare medicines in limited quantities. It does not extend to 503B outsourcing facilities, which are larger operations that produce higher volumes. This distinction creates a potential supply issue for consumers. Joshua Fritzler, president of Olympia and Wesley Pharmaceuticals in central Florida, said his company did not make these peptides before because they were illegal to compound.

Fritzler noted that only the smaller facility of his company will be eligible to produce the compounds under the new rules. He stated that the company will likely only compound one of the six peptides and must first prepare its facility. "We won't be able to meet demand," Fritzler said, adding that he does not think all 503A pharmacies in the country could satisfy consumer interest.

Scott Brunner, CEO of the Alliance for Pharmacy Compounding, said the decision provides a more accountable alternative for patients. He emphasized that the policy brings these products into a system where pharmacy standards and adverse event reporting apply. However, Brunner warned that it may take time for pharmacies to begin dispensing the products because ingredient suppliers must verify that active ingredients meet the new requirements.

Consumer advocacy groups have raised concerns about the speed of the decision. Dr. Robert Steinbrook, Health Research Group Director at Public Citizen, wrote that Kennedy acted unilaterally rather than through the typical rulemaking process. Steinbrook argued that allowing unproven peptides to be manufactured without concern for federal enforcement undermines the FDA and threatens public health. He advised clinicians to inform patients about the risks of contamination and other adverse effects.

The Partnership for Safe Medicines filed a citizen petition last week urging the FDA to ignore the recommendation from its advisory committee in July. Shabbir Safda, the group's executive director, wrote that the decision leaves Americans in a gray area regarding safety. He noted that FDA scientists recommended against unwinding restrictions on these substances due to concerns about the available evidence.